Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents.
作者信息
Platton Sean, Bowles Louise, MacCallum Peter
机构信息
Haemophilia Centre, Barts Health NHS Trust, Royal London Hospital, London, UK.
Queen Mary's School of Medicine and Dentistry, London, UK.
出版信息
Br J Haematol. 2017 Nov;179(3):511-513. doi: 10.1111/bjh.14230. Epub 2016 Jul 8.
PMID:27392166
Abstract
摘要
相似文献
1
Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents.
Br J Haematol. 2017 Nov;179(3):511-513. doi: 10.1111/bjh.14230. Epub 2016 Jul 8.
2
The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
Pathology. 2016 Jan;48(1):60-71. doi: 10.1016/j.pathol.2015.11.025. Epub 2015 Dec 17.
3
Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Clin Appl Thromb Hemost. 2016 Jul;22(5):423-8. doi: 10.1177/1076029616629759. Epub 2016 Feb 2.
4
The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis.
Platelets. 2020;31(1):43-47. doi: 10.1080/09537104.2018.1557618. Epub 2018 Dec 20.
5
Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital.
Br J Haematol. 2022 Jan;196(1):e3-e6. doi: 10.1111/bjh.17757. Epub 2021 Aug 5.
6
The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.
Blood Transfus. 2015 Oct;13(4):666-8. doi: 10.2450/2015.0224-14. Epub 2015 Jan 29.
7
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Thromb Haemost. 2014 Jun;111(6):1133-40. doi: 10.1160/TH13-10-0871. Epub 2014 Jan 9.
8
Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy.
JAMA. 2018 Oct 9;320(14):1485-1486. doi: 10.1001/jama.2018.13998.
9
[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
J Mal Vasc. 2014 May;39(3):183-94. doi: 10.1016/j.jmv.2014.02.001. Epub 2014 Mar 18.
10
Intrinsic coagulant potential modulates anticoagulant efficacy of rivaroxaban.
Thromb Res. 2024 May;237:34-36. doi: 10.1016/j.thromres.2024.03.006. Epub 2024 Mar 15.
引用本文的文献
1
The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence.
J Thromb Thrombolysis. 2023 Apr;55(3):449-463. doi: 10.1007/s11239-023-02776-z. Epub 2023 Feb 6.
Zotero 插件